|
Treatment for First-Episode Schizophrenia Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Treatment for First-Episode Schizophrenia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Treatment for First-Episode Schizophrenia Clinical research trials and Treatment for First-Episode Schizophrenia medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Treatment for First-Episode Schizophrenia. Treatment for First-Episode Schizophrenia Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Treatment for First-Episode Schizophrenia clinical trial. Participants frequently get the best healthcare available for their Treatment for First-Episode Schizophrenia condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Treatment for First-Episode Schizophrenia  Treatment for First-Episode Schizophrenia
Treatment for First-Episode Schizophrenia
For Condition: Schizophrenia
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to see if the newest class of antipsychotic medications can improve the course of patients with first-episode schizophrenia. Schizophrenia patients generally respond very well to their first round of treatment with antipsychotic medications. However, relapses are common, and the condition can worsen over time. The newest class of antipsychotic medications may be able to prevent this, if begun during the first episode of schizophrenia. Patients will be assigned randomly (like tossing a coin) to 3 years of treatment with 1 of 2 antipsychotic medications: olanzapine or risperidone. Response to medication will be monitored, including symptoms, memory and attention, and any side effects. The effects of long-term treatment will be measured, including any relapses. An individual may be eligible for this study if he/she is 16 to 40 years old and is having his/her first episode of schizophrenia.
Details: The goal of the study is to prevent morbidity in first-episode schizophrenia using second-generation antipsychotic drugs: olanzapine, risperidone. Long-term studies of first-episode schizophrenia patients have clearly indicated excellent initial responsiveness of positive psychotic symptoms to treatment with conventional antipsychotic medications. However, in the years immediately following this initial good response, morbidity increases. Relapses, often multiple ones, are the rule and are usually precipitated by medication noncompliance. There is some evidence that the second-generation antipsychotic drugs may have superior efficacy in terms of these outcome domains. However, these newer agents have been studied primarily in chronic and/or treatment-resistant patient samples and there are virtually no long-term studies or studies comparing the new drugs with one another. First episode patients are randomly assigned to treatment with olanzapine or risperidone for 3 years. Outcome measures for the initial episode include psychopathology (positive, negative, and affective symptoms), side effects, neurocognition (executive function, memory, and attention), social and occupational function and service utilization. The effects on long-term course are measured in terms of frequency and timing of relapses, level of recovery from subsequent episodes and prospectively assessed course of psychopathology, neurocognitive function, social/vocational function, and service utilization.
Eligibility:
Study Type: Interventional, Treatment, Randomized
Minimum Age/Maximum Age: 16 Years/40 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: Patients must have: First episode schizophrenia, schizophreniform disorder or schizoaffective disorder Exclusion Criteria: Excluded: Prior treatment with antipsychotic medications.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DelbertRobinson, Principal Investigator, The Zucker Hillside Hospital
Bronx-Lebanon Hospital Center *Recruiting*
Bronx, New York, 10456
United States
Recruiting Beth Lorrel 718-579-7300
Hillside Hospital *Recruiting*
Glen Oaks, New York, 11004
United States
Recruiting Joanne Caponi 718-470-8446
Additional Information:
Study ID Numbers: MH60004;
Study Start Date: September 1998
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000374
Other Schizophrenia Studies:
1. Imaging of Brain Receptors in Healthy Volunteers and in Patients with Schizophrenia
2. CAFE Comparison of Atypicals in First Episode
3. Comparison of Clozapine or Olanzapine in Childhood-Onset Psychotic Disorders
4. Treating Drug-Resistant Childhood Schizophrenia
5. A comparison of Seroquel vs. Risperidone in Schizophrenia
Related Studies:
Other Schizophrenia Clinical Trials
Other New York Clinical Trials
Other Bronx Clinical Trials
Treatment for First-Episode Schizophrenia
|
|
|
|
|
|
|
|
